News
2d
GlobalData on MSNCardurion concludes enrolment in Phase II trials for heart failure treatmentUS-based Cardurion Pharmaceuticals has completed enrolment in two multi-centre, global Phase II CYCLE trials of the ...
A new study published in the European Journal of Medical Research revealed that dapagliflozin, a sodium-glucose ...
Rayan Salih, MD, a third-year internal medicine resident with the Northeast Georgia Health System, who hopes to specialize in cardiology, presented the poster, “Double Trouble: Pregnancy Challenges in ...
Dapagliflozin-spironolactone reduces NT-proBNP levels and blood pressure more than dapagliflozin alone but at the cost of a ...
Left bundle branch block may serve as an important indicator for asymptomatic individuals predisposed to heart failure.
Ultromics has raised $55 million in venture capital funding to expand the reach of its artificial-intelligence-powered ...
A tiny implantable heart device is changing lives for patients with HFpEF heart failure. Scripps La Jolla is among 65 ...
For the HF patient with a gain in LVEF, there’s little guidance on how best to care for them or manage their GDMT.
Detailed price information for Tectonic Therapeutic Inc (TECX-Q) from The Globe and Mail including charting and trades.
13d
MedPage Today on MSNCaution Advised With Upfront SGLT2 Inhibitor-MRA Combo for Heart FailureIncluded in the open-label crossover SOGALDI-PEF study were adults with symptomatic heart failure (New York Heart Association ...
A post hoc analysis of the SUMMIT trial, published in JACC, reveals that baseline body mass index (BMI) and fat distribution ...
The incretin-based therapies reduced mortality and hospitalization risk in individuals with heart failure with preserved ejection fraction.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results